翻訳と辞書 |
Acadia Pharmaceuticals : ウィキペディア英語版 | Acadia Pharmaceuticals
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase IV 〔http://www.utsandiego.com/news/2014/dec/29/acadia-pharmaceuticals-psychosis-drug-Nuplazid/〕 development as a treatment for Parkinson's disease psychosis. It is also developing AGN XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. The product candidates in the company's pipeline emanate from discoveries made using its proprietary drug discovery platform. ==Recent Events==
Acadia Pharmaceuticals extended its drug discovery and development research agreement with Allergan to March 2012. The agreement stipulates both parties will work together for the discovery of new therapeutics for glaucoma and ophthalmic conditions.〔http://finance.yahoo.com/news/Acadia-Pharma-extends-eye-apf-2862915783.html?x=0&.v=1 Acadia Pharma extends eye drug deal with Allergan〕
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Acadia Pharmaceuticals」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|